Suppr超能文献

房室瓣早期干预对 Fontan 术后生存的影响。

Effect of Earlier Atrioventricular Valve Intervention on Survival After the Fontan Operation.

机构信息

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

出版信息

Am J Cardiol. 2020 Dec 15;137:103-110. doi: 10.1016/j.amjcard.2020.09.028. Epub 2020 Sep 28.

Abstract

Whereas the prevalence and impact of atrioventricular valve (AVV) regurgitation in patients with single ventricle physiology has become increasingly apparent, the optimal timing for valve intervention is unclear. To investigate this, we performed a retrospective review of all 1,167 patients from the Mayo Clinic Fontan database. Thirteen percent (153 patients) had AVV repair or replacement during their staged single ventricle palliation. We found that patients with right ventricular morphology and common AVV were at increased risk for AVV intervention. Patients who underwent AVV intervention had increased risk of death/transplant compared with those who did not (hazards ratio [HR] = 1.75, 95% CI 1.37 to 2.23, p <0.001). With respect to valve intervention timing, whereas AVV intervention before Fontan presented similar risk for death/transplant compared with no AVV intervention (HR = 0.85, 95% CI 0.32 to 2.27, p = 0.74), intervention at time of Fontan had a significantly higher risk (HR = 1.46, 95% CI 1.09 to 1.97, p = 0.01), and intervention after Fontan had a much more substantial risk (HR = 3.83, 95% CI 2.54 to 5.79, p <0.001). AVV repair failure occurred in 11% of patients. In terms of relative risk of valve repair versus replacement, in post-Fontan AVV intervention patients, AVV replacement carried a 2.9 fold risk of death/transplant compared with AVV repair. In conclusion, AVV disease remains a considerable challenge for durable Fontan physiology. This data demonstrates that earlier intervention on valve pathology improves survival with the Fontan circulation. Continued surveillance of single ventricle patients and prompt referral of those with valve pathology can improve outcomes in this challenging population.

摘要

虽然在单心室生理患者中心房-心室瓣(AVV)反流的患病率和影响变得越来越明显,但瓣膜介入的最佳时机尚不清楚。为了研究这一点,我们对梅奥诊所 Fontan 数据库中的 1167 名患者进行了回顾性分析。在分期单心室姑息治疗过程中,有 13%(153 名患者)进行了 AVV 修复或置换。我们发现,具有右心室形态和共同 AVV 的患者进行 AVV 干预的风险增加。与未行 AVV 干预的患者相比,行 AVV 干预的患者死亡/移植风险增加(风险比 [HR] = 1.75,95%CI 1.37 至 2.23,p <0.001)。关于瓣膜干预时机,与 Fontan 前 AVV 干预相比,Fontan 时无 AVV 干预的死亡/移植风险相似(HR = 0.85,95%CI 0.32 至 2.27,p = 0.74),Fontan 时的干预风险显著增加(HR = 1.46,95%CI 1.09 至 1.97,p = 0.01),Fontan 后干预的风险更高(HR = 3.83,95%CI 2.54 至 5.79,p <0.001)。11%的患者发生 AVV 修复失败。就瓣膜修复与置换的相对风险而言,在 Fontan 后 AVV 干预患者中,与 AVV 修复相比,AVV 置换的死亡/移植风险增加 2.9 倍。总之,AVV 疾病仍然是持久的 Fontan 生理的一个重大挑战。这些数据表明,早期干预瓣膜病变可提高 Fontan 循环的生存率。对单心室患者的持续监测,并及时转诊有瓣膜病变的患者,可以改善这一具有挑战性人群的结局。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验